Tryptamine Therapeutics Financial Overview
Tryptamine Therapeutics's market cap is currently AU$49.89M. The company's EPS TTM is AU$; its P/E ratio is -7.05; Tryptamine Therapeutics is scheduled to report earnings on ―, and the estimated EPS forecast is AU$―. See an overview of income statement, balance sheet, and cash flow financials.